# Controlled release of bone morphogenetic protein-2 improves motor function after traumatic brain injury in a rat model

**Authors:** Jakob M. Townsend, Jasmine Z. Deng, Scott Barbay, Brian T. Andrews, David J. Guggenmos, Randolph J. Nudo, Michael S. Detamore

PMC · DOI: 10.1039/d5tb02643a · Journal of Materials Chemistry. B · 2026-02-24

## TL;DR

A hydrogel that releases bone morphogenetic protein-2 (BMP-2) improved motor function and reduced brain atrophy in rats after traumatic brain injury.

## Contribution

A novel hydrogel system with controlled BMP-2 release was developed to improve outcomes in traumatic brain injury.

## Key findings

- PHA-TDVT hydrogels with BMP-2 microspheres significantly improved calcium deposition and osteogenic gene expression in vitro.
- BMP-2 microsphere addition reduced motor skill impairment and brain atrophy in vivo.
- The PHA-TDVT + µ100 group showed 2.8 times greater reach index and 2.3 times lower brain atrophy compared to the control.

## Abstract

Severe traumatic brain injury (TBI) is a life-threatening condition characterized by brain swelling within the cranial vault and commonly treated using a two-stage surgical approach. The interval between surgeries, generally spaced weeks to months, is associated with secondary neurologic complications from leaving the brain unprotected. Hydrogels may reshape TBI treatment by enabling a single-stage surgical intervention, capable of being implanted during the initial surgery, remaining flexible to accommodate brain swelling, and calibrated to regenerate bone after brain swelling has subsided. The current study evaluated the use of a pentenoate-modified hyaluronic acid (PHA) polymer with thiolated devitalized tendon (TDVT) for calvarial bone regeneration in a rat TBI model. Additionally, PHA-TDVT hydrogels encapsulating microspheres containing bone morphogenetic protein-2 (BMP-2) were investigated to enhance bone regeneration. All hydrogel precursor formulations exhibited sufficient yield stress for surgical placement. The addition of TDVT to the crosslinked hydrogels increased the average compressive modulus. In vitro cell studies revealed that the PHA-TDVT hydrogel with the highest concentration of BMP-2 microspheres (i.e., PHA-TDVT + µ100) significantly improved calcium deposition and osteogenic gene expression. Minimal in vivo bone regeneration was observed for all hydrogel groups; however, BMP-2 microsphere addition fortuitously reduced motor skill impairment and brain atrophy. The PHA-TDVT + µ100 group had 2.8 times greater reach index and 2.3 times lower brain atrophy values compared to the negative control (p < 0.05). Overall, hydrogels with controlled release of BMP-2 may provide neuroprotective benefits in TBI treatment. Future studies will explore BMP-2 delivery strategies to enhance both bone and brain recovery in rat TBI studies.

Illustration of the traumatic brain injury rat model and implantation of the thiolated devitalized tendon (TDVT) hydrogel delivering PLGA microspheres releasing bone morphogenetic protein (BMP)-2.

## Linked entities

- **Proteins:** BMP2 (bone morphogenetic protein 2)
- **Chemicals:** PLGA (PubChem CID 36797)
- **Diseases:** traumatic brain injury (MONDO:0858950)
- **Species:** Rattus norvegicus (taxon 10116)

## Full-text entities

- **Genes:** BGLAP (bone gamma-carboxyglutamate protein) [NCBI Gene 632] {aka BGP, OC, OCN}, Ntf3 (neurotrophin 3) [NCBI Gene 81737], Vegfa (vascular endothelial growth factor A) [NCBI Gene 83785] {aka VEGF-A, VEGF111, VEGF164, VPF, Vegf}, Bmp4 (bone morphogenetic protein 4) [NCBI Gene 25296] {aka BOMPR4A}, Alb (albumin) [NCBI Gene 24186] {aka Alb1, Albza}, Bmpr2 (bone morphogenetic protein receptor type 2) [NCBI Gene 140590] {aka Bmpr-II}, Pten (phosphatase and tensin homolog) [NCBI Gene 50557] {aka MMAC1, Mmac, TEP1}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56718] {aka Frap1, RAFT1}, BMP2 (bone morphogenetic protein 2) [NCBI Gene 650] {aka BDA2, BMP2A, SSFSC, SSFSC1}, RUNX2 (RUNX family transcription factor 2) [NCBI Gene 860] {aka AML3, CBF-alpha-1, CBFA1, CCD, CCD1, CLCD}, Bmp7 (bone morphogenetic protein 7) [NCBI Gene 85272] {aka BMP-7}, Bmp6 (bone morphogenetic protein 6) [NCBI Gene 25644] {aka VGR}, Pik3cb (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta) [NCBI Gene 85243], Bmp2 (bone morphogenetic protein 2) [NCBI Gene 29373], Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 24383] {aka BARS-38, Gapd}, Bglap (bone gamma-carboxyglutamate protein) [NCBI Gene 25295] {aka Bglap2, Bgp, Bgpr, Bgpra}
- **Diseases:** PHA (MESH:C564098), allodynia (MESH:D006930), necrotic (MESH:D009336), DVT (MESH:D019553), tissue loss (MESH:D017695), DC (MESH:D003665), motor impairment (MESH:D000068079), brain injury (MESH:D001930), brain defect (MESH:D001927), fatality (MESH:C565541), bone (MESH:D001847), acidosis (MESH:D000138), dizziness (MESH:D004244), brain swelling (MESH:D001929), heterotopic ossification (MESH:D009999), impairment of fine motor skills (MESH:D019957), calvarial bone defects (MESH:C537963), stroke (MESH:D020521), CCI (MESH:D004834), cranial defect (MESH:D003389), neurodegeneration (MESH:D019636), headache (MESH:D006261), inflammation (MESH:D007249), pain (MESH:D010146), impairment (MESH:D060825), COLI (MESH:C537702), Brain atrophy (MESH:C566985), TBI (MESH:D000070642), neurologic complications (MESH:D002493), swelling (MESH:D004487), atrophy (MESH:D001284)
- **Chemicals:** Bupivacaine (MESH:D002045), l-cysteine (MESH:D003545), DMF (MESH:D004126), TCP (MESH:C049563), iodine (MESH:D007455), buprenorphine (MESH:D002047), methacrylate (MESH:D008689), PLGA (MESH:D000077182), eosin (MESH:D004801), PBS (MESH:D007854), alcohol (MESH:D000438), lithium phenyl-2,4,6-trimethylbenzoylphosphinate (MESH:C546776), Calcium (MESH:D002118), Cat# D218200 (-), silicon (MESH:D012825), ioversol (MESH:C054871), H&amp;E (MESH:D006371), procaine (MESH:D011343), penicillin (MESH:D010406), sodium phosphate (MESH:C018279), Hematoxylin (MESH:D006416), polyvinyl alcohol (MESH:D011142), beta-glycerophosphate (MESH:C031463), Thiol (MESH:D013438), hydroxylamine hydrochloride (MESH:D019811), ascorbic acid-2-phosphate (MESH:C011669), 4-(dimethylamino)pyridine (MESH:C000607852), acetone (MESH:D000096), benzathine (MESH:C010044), Water (MESH:D014867), isoflurane (MESH:D007530), DTT (MESH:D004229), alpha-MEM (MESH:C420642), Cresyl violet (MESH:C028911), Ellman's reagent (MESH:D004228), acetic acid (MESH:D019342), hydrochloric acid (MESH:D006851), ethanol (MESH:D000431), NaOH (MESH:D012972), HA (MESH:D006820), N-Succinimidyl S-acetylthioacetate (MESH:C039011), EMLA (MESH:D000077442), paraffin (MESH:D010232), methanol (MESH:D000432), P/S (MESH:D010758), acetaminophen (MESH:D000082), xylene (MESH:D014992), EDTA (MESH:D004492), DCM (MESH:D008752), PVA (MESH:C063253), ethylene oxide (MESH:D005027), streptomycin (MESH:D013307), polymer (MESH:D011108)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** C > D, C with a 12, E > F
- **Cell lines:** PHA — Homo sapiens (Human), Neuroblastoma, Cancer cell line (CVCL_D044)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12947964/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12947964/full.md

## References

73 references — full list in the complete paper: https://tomesphere.com/paper/PMC12947964/full.md

---
Source: https://tomesphere.com/paper/PMC12947964